Core Viewpoint - The announcement from Shenglian Bio indicates significant progress in the clinical trial of the innovative drug UB-221, which is aimed at treating chronic spontaneous urticaria (CSU) [1] Group 1: Clinical Trial Details - The clinical trial for UB-221 is a Phase II, multi-center, randomized, double-blind, placebo-controlled, parallel-group study [1] - A total of 145 subjects have been enrolled, surpassing the initial target of 144 patients [1] - Patients are randomly assigned to one of five treatment groups, receiving either 4mg/kg UB-221, 2mg/kg UB-221, 1mg/kg UB-221, 300mg Xolair, or a placebo [1] Group 2: Study Objectives - The primary endpoint of the trial is the percentage of patients achieving HSS7=0 at week 12 [1] - UB-221 is developed as a next-generation product by Dr. Zhang Ziwen, the inventor of the anti-IgE treatment method [1] Group 3: Company Background - UB-221 is a humanized original monoclonal antibody in a subcutaneous injection form, developed by the second-largest shareholder, United Biomedical, Inc. [1]